Vertaling van "risk of transmission from " (Nederlands → Frans) :

The risk of transmission from a non-isolated patient is 16 to 38 times 11,12 higher than from isolated patients.
Le risque de transmission à partir d'un patient non isolé est 16 à 38 fois plus élevé qu’à partir de patients isolés 11,12 .

Risk of hepatitis B and human immunodeficiency virus transmission to a patient from an infected surgeon due to percutaneous injury during an invasive procedure: estimates based on a model.
Risk of hepatitis B and human immunodeficiency virus transmission to a patient from an infected surgeon due to percutaneous injury during an invasive procedure : estimates based on a model.

To minimise the risk of MRSA transmission by contacts with the patients and their families during transfer between healthcare facilities, it is recommended to provide clear information to the patients and their relatives about the significance of MRSA carriage and the precautions to be taken to limit its dissemination.
Afin de réduire au minimum le risque de transmission de MRSA par les contacts avec les patients ou leur famille au cours du transfert entre les installations des établissements de soins de santé, il est recommandé d’informer clairement le patient et sa famille de la signification du portage de MRSA et des précautions à prendre pour en limiter la dissémination.

vCJD transmission by blood », European Commission Health and Consumer Protection Directorate-General, October 2004, 13 bladzijden. d) Enquête EC Public Health and Risk Assessment « Precautionary measures against
vCJD transmission by blood », European Commission Health and Consumer Protection Directorate-General, October 2004, 13 pages. d) Enquête EC Public Health and Risk Assessment « Precautionary measures against

Gunson RN, Shouval D, Roggendorf M, Zaaijer H, Nicholas H, Holzmann H, et al. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients.
Gunson RN, Shouval D, Roggendorf M, Zaaijer H, Nicholas H, Holzmann H, et al. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs) : guidelines for prevention of transmission of HBV and HCV from HCW to patients.

Referentie: Transmissible spongiform encephalopathy agents: safe working and the prevention of infection, Annexe A.1, Guidance from the Advisory Committee on Dangerous Pathogens and the Spongiform Encephalopathy Advisory Committee, Department of Health UK, 2003.
Référence: Transmissible spongiform encephalopathy agents: safe working and the prevention of infection, Annexe A.1 , Guidance from the Advisory Committee on Dangerous Pathogens and the Spongiform Encephalopathy Advisory Committee, Department of Health UK, 2003.

Results from a Phase III study involving Afinitor in pancreatic neuroendocrine tumors (NET), a rare and aggressive form of cancer with limited treatment options, showed that Afinitor extended median progression-free survival from 4.6 to 11 months versus placebo and reduced the risk of cancer progression by 65%.
(TNE) du pancréas, une forme rare et agressive de cancer difficile à traiter, ont montré qu’Afinitor allongeait la survie moyenne sans progression de la maladie de 4,6 à 11 mois par rapport à un placebo et réduisait de 65% le risque de progression du cancer.

This section will therefore present an overview of a model of the risk and protective factors that was devised as means to understand the dynamics behind depression. Next, it will turn to a model of the risk and protective factors from the Suicide Prevention Resource Centre of the American foundation for Suicide Prevention that focuses specifically on suicide.
Nous présenterons donc dans cette section un résumé d’un modèle de facteurs de risque et de protection élaboré pour appréhender la dynamique liée à la dépression et, dans un second temps, un modèle des facteurs de risque et de protection plus spécifique au suicide du Suicide Prevention Ressource Center de l’American foundation for Suicide Prevention.

We adopt a risk-based approach and focus on minimizing our use of natural resources, cutting our energy consumption and emissions, and preventing active ingredients from entering the environment.
Notre approche est basée sur une évaluation des risques ; nous nous efforçons de réduire au minimum notre exploitation des ressources naturelles, d’abaisser notre consommation d’énergie et nos émissions de gaz polluants dans l’air, et nous prenons toutes les mesures adéquates pour empêcher les émanations de substances actives en dehors de nos laboratoires.

Results from the Japanese KYOTO HEART study, presented in September at the European Society of Cardiology Congress, demonstrated that the addition of Diovan to a non-ARB-based treatment regimen for high blood pressure provided a significant 45% relative risk reduction in cardiovascular events, including stroke, over a conventional non-ARB treatment regimen.
Les résultats de l’étude japonaise KYOTO HEART, présentés au Congrès de la Société Européenne de Cardiologie, ont prouvé que l’adjonction de Diovan lors d’un traitement contre l’hypertension non basé sur les ARA a conduit à une réduction importante de 45% du risque relatif d’accidents cardiovasculaires, notamment cérébraux, par rapport à un traitement non ARA conventionnel.